| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TTC |
| Uniprot No | Q8WVT3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-735aa |
| 氨基酸序列 | MEDAGGGEETPAPEAPHPPQLAPPEEQGLLFQEETIDLGGDEFGSEENETASEGSSPLADKLNEHMMESVLISDSPNSEGDAGDLGRVRDEAEPGGEGDPGPEPAGTPSPSGEADGDCAPEDAAPSSGGAPRQDAAREVPGSEAARPEQEPPVAEPVPVCTIFSQRAPPASGDGFEPQMVKSPSFGGASEASARTPPQVVQPSPSLSTFFGDTAASHSLASDFFDSFTTSAFISVSNPGAGSPAPASPPPLAVPGTEGRPEPVAMRGPQAAAPPASPEPFAHIQAVFAGSDDPFATALSMSEMDRRNDAWLPGEATRGVLRAVATQQRGAVFVDKENLTMPGLRFDNIQGDAVKDLMLRFLGEKAAAKRQVLNADSVEQSFVGLKQLISCRNWRAAVDLCGRLLTAHGQGYGKSGLLTSHTTDSLQLWFVRLALLVKLGLFQNAEMEFEPFGNLDQPDLYYEYYPHVYPGRRGSMVPFSMRILHAELQQYLGNPQESLDRLHKVKTVCSKILANLEQGLAEDGGMSSVTQEGRQASIRLWRSRLGRVMYSMANCLLLMKDYVLAVEAYHSVIKYYPEQEPQLLSGIGRISLQIGDIKTAEKYFQDVEKVTQKLDGLQGKIMVLMNSAFLHLGQNNFAEAHRFFTEILRMDPRNAVANNNAAVCLLYLGKLKDSLRQLEAMVQQDPRHYLHESVLFNLTTMYELESSRSMQKKQALLEAVAGKEGDSFNTQCLKLA |
| 预测分子量 | 79,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TTC(Tetanus Toxin C-fragment)重组蛋白的参考文献摘要示例(注：以下内容为模拟概括，具体文献需根据实际检索验证)：
1. **文献名称**: "A recombinant tetanus toxin C-fragment for targeted drug delivery"
**作者**: Lee S., et al.
**摘要**: 研究利用重组TTC蛋白的神经元靶向特性，开发新型药物递送系统，证明其可有效穿透血脑屏障并促进药物在中枢神经系统的富集。
2. **文献名称**: "Expression and purification of a heat-stable TTC fusion protein in E. coli"
**作者**: Zhang Y., et al.
**摘要**: 报道一种新型重组TTC融合蛋白的优化表达工艺，通过引入热稳定性突变体提升蛋白产量和稳定性，为疫苗载体开发提供技术基础。
3. **文献名称**: "TTC-conjugated vaccines enhance antigen-specific immune responses"
**作者**: Fernández M.V., et al.
**摘要**: 验证TTC作为疫苗载体蛋白的佐剂效应，证明其与抗原融合后能显著增强小鼠模型中的抗体滴度及T细胞免疫应答。
建议通过PubMed或Google Scholar搜索关键词 *"Tetanus toxin C-fragment recombinant"* 或 *"TTC fusion protein"* 获取最新具体文献。部分经典研究可能发表于《Vaccine》《Biotechnology Journal》等期刊。
**Background of TTC Recombinant Protein**
TTC (tetanus toxin C-fragment) recombinant protein is a key component derived from *Clostridium tetani*, the bacterium responsible for tetanus. The native tetanus toxin consists of a heavy chain (Hc) and a light chain (Lc), where the Hc mediates neuronal cell binding and internalization, while the Lc acts as a zinc-dependent protease causing neurotoxic effects. The C-terminal fragment of the heavy chain, TTC (approximately 50 kDa), retains the receptor-binding domain but lacks the toxic enzymatic activity, making it a non-toxic, immunogenic candidate for biomedical applications.
Recombinant TTC is produced using genetic engineering techniques, where the *tetC* gene encoding TTC is cloned into expression vectors (e.g., *E. coli* or mammalian systems) and purified for research or therapeutic use. Its ability to bind neuronal surface receptors, particularly at neuromuscular junctions, has been exploited in neuroscience for neuronal tracing and drug delivery. Additionally, TTC serves as a carrier protein in conjugate vaccines, enhancing immune responses against weakly immunogenic antigens.
In vaccine development, TTC’s strong immunogenicity and safety profile have made it a critical component of tetanus vaccines. It is also studied for targeted therapies, such as delivering neuroprotective agents or gene therapies to specific neural cells. Recent research explores TTC-based fusion proteins for treating neurodegenerative diseases and improving vaccine efficacy. Overall, TTC recombinant protein bridges microbiology, immunology, and biotechnology, offering versatile tools for both preventive and therapeutic innovations.
×
